Company History

Since our establishment in 1982, SYN-TECH has adhered to the business philosophy of "Integrity, Pragmatism, Innovation, and Development."
Through continuous investment in R&D and facility expansion, we have gradually grown into an internationally competitive API manufacturer.
Below are the major milestones in our company's development:

Year	Company Milestones
1982	SYN-TECH CHEM. & PHARM. CO., LTD. was established with a registered capital of NT$12 million.
1983	Plant A and Plant B construction completed. Obtained API drug licenses from the Department of Health, Executive Yuan, and officially began API production and sales.
1987	1. Capital increased by NT$6 million to NT$18 million. 2. Completed a wastewater treatment facility capable of processing 50 tons per day and waste gas treatment equipment, both operational.
1988	Plant C construction completed and began production of new products.
1989	Capital increased by NT$12 million to NT$30 million.
1990	Office, quality control, and research building construction completed.
1991	1. Capital increased by NT$30 million to NT$60 million. 2. GMP-compliant Plant B renovation completed. 3. Acquired additional 3,673 m² of land, expanding total land area to 12,852 m².
1992	Planned GMP-compliant Plant E and a large-scale comprehensive wastewater treatment facility capable of processing 150 tons per day with high-efficiency waste gas treatment equipment. Construction began in July and was completed in 1993.
1993	Capital increased by NT$12 million from retained earnings to NT$72 million.
1994	Obtained US FDA approval for company facilities and equipment under DMF 11038.
1995	1. Capital increased by NT$28 million through debt-to-equity conversion to NT$100 million. 2. Products passed US FDA on-site inspection, enabling export to the United States.
1996	1. Capital increased by NT$32 million to NT$132 million. 2. ANTICHOLESTERMIC COMPOUNDS received US Patent: 5530145.
1997	1. Capital increased by NT$18 million to NT$150 million. 2. Plants A and B renovated to meet GMP standards, completed the following year.
1998	1. Plant D renovated to meet GMP standards, completed the following year. 2. Received National Pharmaceutical Quality Award in both Overall API Manufacturing Plant and Single Drug Product categories. Obtained ISO 9001 international quality certification.
1999	1. Three products passed US FDA on-site inspection; one product received Innovation Research Award from Small and Medium Enterprise Administration. 2. Received 2nd Small Giant Award from Asia-Pacific Industrial R&D Foundation.
2000	Obtained ISO 14001 environmental management system certification and selected as an outstanding ISO 14001 demonstration team by the Industrial Development Bureau, Ministry of Economic Affairs.
2001	Passed rigorous inspections by world-leading pharmaceutical companies, with our APIs being adopted for their products.
2002	1. Capital increased by NT$15 million from retained earnings and NT$20 million cash injection to NT$185 million. 2. Received 3rd Industrial Sustainability Elite Award and 11th National Cornerstone Award.
2003	1. Company stock approved for public offering by Securities and Futures Commission, Ministry of Finance. 2. Complete re-election of board and supervisors, adding 2 independent directors and 1 independent supervisor. 3. Capital increased by NT$9.25 million from retained earnings to NT$194.25 million. 4. Received 3rd Pharmaceutical Science and Technology R&D Award from Department of Health.
2004	1. Plant C renovation completed to meet GMP standards. 2. Company stock listed on Emerging Stock Market. 3. Received 11th Small and Medium Enterprise Innovation Research Award from Ministry of Economic Affairs. 4. Obtained OHSAS 18001 occupational safety and health management system certification. 5. Received API cGMP Award from Department of Health. 6. Applied for OTC listing on July 29, 2004.
2005	1. Capital increased by NT$21.85 million through public offering for OTC listing to NT$216.1 million. 2. Officially listed on OTC market on October 19, 2005.
2006	Passed inspections by 12 leading pharmaceutical companies from Europe, America, and Japan, with gradual adoption of our APIs.
2007	1. Received commendation for outstanding performance in Clean Homeland Campaign by Environmental Protection Administration. 2. Passed inspections by US and Korean FDA. 3. Two products passed Department of Health API cGMP inspection. 4. Received 8th National Standardization Award from Bureau of Standards, Metrology and Inspection, Ministry of Economic Affairs.
2008	1. Plant E renovation completed to meet GMP standards. 2. Passed inspection by Hungarian government. 3. Passed follow-up API cGMP inspection by Department of Health.
2009	1. Received 8th Pharmaceutical Science and Technology R&D Award jointly organized by Department of Health and Ministry of Economic Affairs. 2. Obtained ISO 9001:2008 international quality management system certification. 3. Listed as one of 2010 Global Views CSR Top 65 Enterprises by Common Wealth Magazine. 4. Capital increased by NT$21.61 million from retained earnings to NT$237.71 million.
2010	Five products passed Department of Health API cGMP inspection.
2011	1. Three products passed Department of Health API cGMP inspection. 2. Received 8th National Innovation Award from Biotechnology and Pharmaceutical Industry Promotion Office. 3. Received 18th Small and Medium Enterprise Innovation Research Award from Small and Medium Enterprise Administration, Ministry of Economic Affairs.
2012	1. Passed US FDA inspection. 2. Two more products passed Korean FDA inspection. 3. Capital increased by NT$11.8855 million from retained earnings to NT$249.5955 million. 4. Received recognition as an outstanding company in GDP (Good Distribution Practice) guidance inspection by Food and Drug Administration, Ministry of Health and Welfare.
2013	1. Added 2 products to Japan PMDA DMF registration, bringing total JDMFs to 10. 2. Added 1 product to US DMF registration, bringing total USDMFs to 21. 3. Passed EHS audits by Orion and Johnson & Johnson for green pharmaceuticals and performance indicators.
2014	1. Added 2 products to Japan DMF registration, bringing total MFs to 12. 2. Added 1 product to US DMF registration, bringing total DMFs to 22. 3. Added 1 product to Canada DMF registration, bringing total DMs to 4. 4. Three products passed Ministry of Health and Welfare API cGMP inspection, total of 29. 5. Cash capital increase of NT$51 million to NT$300.5955 million. 6. Received 2014 Pharmaceutical Science and Technology R&D Award from Ministry of Health and Welfare and Ministry of Economic Affairs.
2015	1. Passed Japan PMDA inspection for 2 products. 2. Passed US FDA inspection. 3. Added 1 product to Japan DMF registration, bringing total MFs to 13. 4. Added 1 product to US DMF registration, bringing total DMFs to 23. 5. Seven products passed Ministry of Health and Welfare API cGMP inspection, total of 36. 6. Corporate Social Responsibility (CSR) certification obtained.
2016	1. Administrative and R&D building expansion began. 2. Passed Mexico COFEPRIS inspection. 3. Added 3 products to Japan DMF registration, bringing total MFs to 16. 4. Added 1 product to US DMF registration, bringing total DMFs to 24. 5. Five products passed Ministry of Health and Welfare API cGMP inspection, total of 41. 6. Wastewater treatment facility expansion began, scheduled for completion in 2017. 7. Finished goods warehouse construction began, scheduled for completion in 2017.
2017	1. Administrative and R&D building expansion completed. 2. Solar power system completed and officially commissioned in support of government green energy policy. 3. Passed rigorous EU EDQM inspection. 4. Ranked in top 5% of OTC companies in corporate governance evaluation for three consecutive years. 5. Added 4 products to Japan DMF registration, bringing total MFs to 20.
2018	1. Plant G expansion completed and passed TFDA GMP evaluation. 2. Passed Japan PMDA inspection for 2 products. 3. Ranked in top 5% of OTC companies in corporate governance evaluation for four consecutive years. 4. Finished goods warehouse construction completed.
2019	1. Passed US FDA inspection. 2. Loading dock construction completed, improving safety and efficiency. 3. Passed Japan PMDA inspection for 1 product.
2020	1. Added 1 product to Japan DMF registration, bringing total MFs to 22. 2. Authorized capital increased to NT$600 million. 3. Collaborated with Germany's TRANSO-PHARM to develop EPR and EPT for hypotension and shock treatment, successfully completing DMF and CEP registrations across Europe, America, Asia, Africa, and Australia.
2021	1. Cash capital increase of NT$100 million to NT$400.5955 million. 2. Received 2021 National Innovation Award Continued Excellence Award from Biotechnology and Medical Technology Policy Research Center. 3. Added 1 product to Japan DMF registration. 4. Added 1 product to Korea DMF registration.
2022	1. Added 1 product to US DMF registration. 2. Issued 4,532,163 new shares for acquisition of Standard Chem. & Pharm. Co., Ltd.'s synthesis department under M&A Act, capital increased to NT$445.917130 million. 3. Added 1 product to China DMF registration. 4. Passed Ministry of Health and Welfare follow-up API cGMP inspection and GDP compliance evaluation.
2023	1. Acquired Standard Chem synthesis department and transferred 14 drug permits and 5 veterinary drug permits. 2. Plant D reconstruction completed and passed TFDA GMP/GDP evaluation. 3. Plant T renovation completed and passed Council of Agriculture GMP evaluation. 4. Plants C and S reconstruction completed and passed TFDA GMP/GDP evaluation. 5. Added 2 products to China DMF registration. 6. Added 2 products to EU DMF registration. 7. Added 1 product to Canada DMF registration. 8. Added 2 products to US DMF registration.
2024	1. Plants E and F reconstruction completed and underwent TFDA GMP/GDP evaluation. 2. Added 1 product to China DMF registration. 3. Received Healthy Workplace Certification - Health Start Badge from Health Promotion Administration, Ministry of Health and Welfare.